🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

India's Metropolis Healthcare $174 mln IPO over subscribed

Published 05-04-2019, 07:04 pm
Updated 05-04-2019, 07:10 pm
© Reuters.  India's Metropolis Healthcare $174 mln IPO over subscribed
CG
-
EMBA
-
RAIV
-
METP
-

April 5 (Reuters) - Metropolis Healthcare Ltd's METP.NS initial public offering (IPO) to raise as much as 12.04 billion rupees ($174.01 million)was over subscribed 5.8 times at the end of the book-running process, stock exchange data showed https:// on Friday.

Of the 13.7 million shares the Indian diagnostics company intends to sell, promoter Sushil Kanubhai Shah will give up 6.3 million shares, while investor CA Lotus Investments, a unit of U.S.-based private equity firm Carlyle Group CG.O , will offload 7.4 million shares.

The IPO includes an anchor portion of about 6 million shares.

Of the remaining shares, investors bid for about 44.6 million shares in the company, or 5.8 times the 7.7 million on offer, as of 0115 GMT.

Interest for Indian equities has seen a rise recently as the country heads for its general elections next week, amid hopes that the current coalition government led by Prime Minister Narendra Modi would return to power, even though investors continued to maintain a cautious stance.

Over the last month, India's state-owned Rail Vikas Nigam Ltd RAIV.NS and the first ever real estate investment trust in India, Embassy Office Parks REIT EMBA.NS have seen successful subscriptions. = 69.1930 Indian rupees)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.